Advancements in the pathogenesis of hepatic osteodystrophy and the potential therapeutic of mesenchymal stromal cells
Abstract Hepatic osteodystrophy (HOD) is a metabolically associated bone disease mainly manifested as osteoporosis with the characteristic of bone loss induced by chronic liver disease (CLD). Due to its high incidence in CLD patients and increased risk of fracture, the research on HOD has received c...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-12-01
|
| Series: | Stem Cell Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13287-023-03605-z |
| _version_ | 1797388490534551552 |
|---|---|
| author | Senzhe Xia Xueqian Qin Jinglin Wang Haozhen Ren |
| author_facet | Senzhe Xia Xueqian Qin Jinglin Wang Haozhen Ren |
| author_sort | Senzhe Xia |
| collection | DOAJ |
| description | Abstract Hepatic osteodystrophy (HOD) is a metabolically associated bone disease mainly manifested as osteoporosis with the characteristic of bone loss induced by chronic liver disease (CLD). Due to its high incidence in CLD patients and increased risk of fracture, the research on HOD has received considerable interest. The specific pathogenesis of HOD has not been fully revealed. While it is widely believed that disturbance of hormone level, abnormal secretion of cytokines and damage of intestinal barrier caused by CLD might jointly affect the bone metabolic balance of bone formation and bone absorption. At present, the treatment of HOD is mainly to alleviate the bone loss by drug treatment, but the efficacy and safety are not satisfactory. Mesenchymal stromal cells (MSCs) are cells with multidirectional differentiation potential, cell transplantation therapy based on MSCs is an emerging therapeutic approach. This review mainly summarized the pathogenesis and treatment of HOD, reviewed the research progress of MSCs therapy and the combination of MSCs and scaffolds in the application of osteoporotic bone defects, and discussed the potential and limitations of MSCs therapy, providing theoretical basis for subsequent studies. |
| first_indexed | 2024-03-08T22:41:35Z |
| format | Article |
| id | doaj.art-9999214eb2d04ff1b40ada20282d624f |
| institution | Directory Open Access Journal |
| issn | 1757-6512 |
| language | English |
| last_indexed | 2024-03-08T22:41:35Z |
| publishDate | 2023-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Stem Cell Research & Therapy |
| spelling | doaj.art-9999214eb2d04ff1b40ada20282d624f2023-12-17T12:08:45ZengBMCStem Cell Research & Therapy1757-65122023-12-0114111210.1186/s13287-023-03605-zAdvancements in the pathogenesis of hepatic osteodystrophy and the potential therapeutic of mesenchymal stromal cellsSenzhe Xia0Xueqian Qin1Jinglin Wang2Haozhen Ren3Department of Oncological Surgery, Wenzhou Central HospitalDivision of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Medical School, Nanjing UniversityDivision of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Nanjing UniversityDivision of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Nanjing UniversityAbstract Hepatic osteodystrophy (HOD) is a metabolically associated bone disease mainly manifested as osteoporosis with the characteristic of bone loss induced by chronic liver disease (CLD). Due to its high incidence in CLD patients and increased risk of fracture, the research on HOD has received considerable interest. The specific pathogenesis of HOD has not been fully revealed. While it is widely believed that disturbance of hormone level, abnormal secretion of cytokines and damage of intestinal barrier caused by CLD might jointly affect the bone metabolic balance of bone formation and bone absorption. At present, the treatment of HOD is mainly to alleviate the bone loss by drug treatment, but the efficacy and safety are not satisfactory. Mesenchymal stromal cells (MSCs) are cells with multidirectional differentiation potential, cell transplantation therapy based on MSCs is an emerging therapeutic approach. This review mainly summarized the pathogenesis and treatment of HOD, reviewed the research progress of MSCs therapy and the combination of MSCs and scaffolds in the application of osteoporotic bone defects, and discussed the potential and limitations of MSCs therapy, providing theoretical basis for subsequent studies.https://doi.org/10.1186/s13287-023-03605-zHepatic osteodystrophyChronic liver diseaseMesenchymal stromal cellScaffold material |
| spellingShingle | Senzhe Xia Xueqian Qin Jinglin Wang Haozhen Ren Advancements in the pathogenesis of hepatic osteodystrophy and the potential therapeutic of mesenchymal stromal cells Stem Cell Research & Therapy Hepatic osteodystrophy Chronic liver disease Mesenchymal stromal cell Scaffold material |
| title | Advancements in the pathogenesis of hepatic osteodystrophy and the potential therapeutic of mesenchymal stromal cells |
| title_full | Advancements in the pathogenesis of hepatic osteodystrophy and the potential therapeutic of mesenchymal stromal cells |
| title_fullStr | Advancements in the pathogenesis of hepatic osteodystrophy and the potential therapeutic of mesenchymal stromal cells |
| title_full_unstemmed | Advancements in the pathogenesis of hepatic osteodystrophy and the potential therapeutic of mesenchymal stromal cells |
| title_short | Advancements in the pathogenesis of hepatic osteodystrophy and the potential therapeutic of mesenchymal stromal cells |
| title_sort | advancements in the pathogenesis of hepatic osteodystrophy and the potential therapeutic of mesenchymal stromal cells |
| topic | Hepatic osteodystrophy Chronic liver disease Mesenchymal stromal cell Scaffold material |
| url | https://doi.org/10.1186/s13287-023-03605-z |
| work_keys_str_mv | AT senzhexia advancementsinthepathogenesisofhepaticosteodystrophyandthepotentialtherapeuticofmesenchymalstromalcells AT xueqianqin advancementsinthepathogenesisofhepaticosteodystrophyandthepotentialtherapeuticofmesenchymalstromalcells AT jinglinwang advancementsinthepathogenesisofhepaticosteodystrophyandthepotentialtherapeuticofmesenchymalstromalcells AT haozhenren advancementsinthepathogenesisofhepaticosteodystrophyandthepotentialtherapeuticofmesenchymalstromalcells |